NO995231L - Terapeutisk behandling av hudlidelser - Google Patents

Terapeutisk behandling av hudlidelser

Info

Publication number
NO995231L
NO995231L NO995231A NO995231A NO995231L NO 995231 L NO995231 L NO 995231L NO 995231 A NO995231 A NO 995231A NO 995231 A NO995231 A NO 995231A NO 995231 L NO995231 L NO 995231L
Authority
NO
Norway
Prior art keywords
therapeutic treatment
skin disorders
vascular permeability
dermatitis
phemigoid
Prior art date
Application number
NO995231A
Other languages
English (en)
Norwegian (no)
Other versions
NO995231D0 (no
Inventor
Michael R Jirousek
Lawrence E Stramm
Louis Vignati
Douglas K Ways
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO995231D0 publication Critical patent/NO995231D0/no
Publication of NO995231L publication Critical patent/NO995231L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
NO995231A 1997-04-30 1999-10-26 Terapeutisk behandling av hudlidelser NO995231L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4443197P 1997-04-30 1997-04-30
PCT/US1998/007808 WO1998048795A1 (fr) 1997-04-30 1998-04-21 Traitement therapeutique des affections cutanees

Publications (2)

Publication Number Publication Date
NO995231D0 NO995231D0 (no) 1999-10-26
NO995231L true NO995231L (no) 1999-12-27

Family

ID=21932346

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995231A NO995231L (no) 1997-04-30 1999-10-26 Terapeutisk behandling av hudlidelser

Country Status (16)

Country Link
US (1) US6093740A (fr)
EP (1) EP0903145A3 (fr)
JP (1) JP2002501501A (fr)
KR (1) KR20010020381A (fr)
CN (1) CN1259866A (fr)
AU (1) AU7131898A (fr)
BR (1) BR9809343A (fr)
CA (1) CA2289257A1 (fr)
EA (1) EA199900987A1 (fr)
HU (1) HUP0002836A2 (fr)
ID (1) ID23528A (fr)
IL (1) IL132520A0 (fr)
NO (1) NO995231L (fr)
PL (1) PL336760A1 (fr)
TR (1) TR199902682T2 (fr)
WO (1) WO1998048795A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE300957T1 (de) * 1998-12-22 2005-08-15 Genentech Inc Antagonisten von vaskular-endothelialen zellwachstumsfaktoren und ihre anwendung
CA2395136A1 (fr) * 1999-12-22 2001-06-28 The Scripps Research Institute Modulateurs et inhibiteurs de la permeabilite angiogenique et vasculaire
US8846039B2 (en) * 2002-04-26 2014-09-30 Asan Laboratories Company (Cayman), Limited Method for ameliorating pruritus
US8163764B2 (en) * 2002-04-26 2012-04-24 Asan Laboratories Company (Cayman) Limited Skincare methods
TWI324604B (en) 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
US20070032479A1 (en) * 2003-12-03 2007-02-08 Leventer Steven M Treatment of inflammatory disorders of the epithelium with low dose 2,3-benzodiazepines
DE102004019413A1 (de) * 2004-04-19 2005-11-24 Phenos Gmbh Hemmung der Proteinkinase C epsilon zur Behandlung von Krankheiten
US8367609B2 (en) * 2006-01-18 2013-02-05 The General Hospital Corporation Methods of reducing skin damage and edema
US7455447B2 (en) * 2006-05-19 2008-11-25 Mediatek Inc. Method and apparatus for a portable device
CN101380317B (zh) * 2007-09-07 2010-12-08 英属开曼群岛商安盛开发药物股份有限公司 减缓搔痒症的药学组合物
ES2633343T3 (es) * 2011-06-13 2017-09-20 The Board Of Trustees Of The University Of Illionis Composiciones de péptidos y métodos para tratar lesión pulmonar, asma, anafilaxis, angioedema, síndromes de permeabilidad vascular sistémica y congestión nasal
WO2018118874A1 (fr) * 2016-12-19 2018-06-28 Chromaderm, Inc. Méthodes de traitement de troubles de l'hyperpigmentation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ227850A (en) * 1988-02-10 1991-11-26 Hoffmann La Roche Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders
AU687909B2 (en) * 1993-12-07 1998-03-05 Eli Lilly And Company Protein kinase C inhibitors
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
HUT69164A (en) * 1993-12-07 1995-08-28 Lilly Co Eli Improved process for producing bis-indolyl-maleimide derivatives
US5545636A (en) * 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
US5481003A (en) * 1994-06-22 1996-01-02 Eli Lilly And Company Protein kinase C inhibitors
US5491242A (en) * 1994-06-22 1996-02-13 Eli Lilly And Company Protein kinase C inhibitors
SI0776895T1 (en) * 1995-11-20 1999-04-30 Eli Lilly And Company Protein kinase C inhibitor
UA54427C2 (uk) * 1996-05-01 2003-03-17 Елі Ліллі Енд Компані Спосіб лікування очних захворювань, які пов'язані з фактором васкулярного ендотеліального росту
BR9710706A (pt) * 1996-05-01 1999-08-17 Lilly Co Eli Tratamento terap-utico para doen-as relacionadas a vegf

Also Published As

Publication number Publication date
EP0903145A3 (fr) 2001-02-07
WO1998048795A1 (fr) 1998-11-05
PL336760A1 (en) 2000-07-17
US6093740A (en) 2000-07-25
BR9809343A (pt) 2000-07-04
CA2289257A1 (fr) 1998-11-05
HUP0002836A2 (hu) 2001-02-28
EA199900987A1 (ru) 2000-08-28
IL132520A0 (en) 2001-03-19
TR199902682T2 (xx) 2000-05-22
AU7131898A (en) 1998-11-24
CN1259866A (zh) 2000-07-12
ID23528A (id) 2000-04-27
NO995231D0 (no) 1999-10-26
KR20010020381A (ko) 2001-03-15
EP0903145A2 (fr) 1999-03-24
JP2002501501A (ja) 2002-01-15

Similar Documents

Publication Publication Date Title
NO995231L (no) Terapeutisk behandling av hudlidelser
WO2002036072A3 (fr) Procede pour une dosimetrie de medicaments a court et a long terme
HK1083203A1 (en) The use of intratumorally administered lactoferrin in the treatment of malignant neoplasms
AU6825300A (en) Compounds
WO2006060507A3 (fr) Procedes et compositions d'utilisation de composes immunomodulatoires pour le traitement des troubles d'immunodeficience
CA2253613A1 (fr) Traitement therapeutique pour les maladies oculaires liees au vegf
NO985066L (no) Terapeutisk behandling for VEGF-relaterte sykdommer
NO954878L (no) Pyrrolderivater
WO2005037323A3 (fr) Methode pour inhiber une signalisation de nf-kappa b et son utilisation pour traiter et pour prevenir des maladies humaines
EP1631297A4 (fr) Traitement des maladies a mediation immunologique au moyen de composes a base de vitamine d active, seuls ou en association avec d'autres agents therapeutiques
WO2000018316A3 (fr) Composition ophtalmique agreable, a liberation prolongee, et procede de therapie oculaire
AU3476397A (en) Therapeutic treatment for cardiovascular diseases
SE9300971D0 (sv) Hudvaardskomposition
CA2441461A1 (fr) Formulations en application locale pour l'administration transdermique de niacine, et procedes pour traiter l'hyperlipemie
TR200102512T2 (tr) Tüm ruhsal bozukluklar, adaptasyon bozuklukları ve çeşitli kaygı-depresyon bozukluklarının tedavisinde ya da önlenmesinde yararlı tıbbi ürünlerin hazırlanması için saredutan ve onun farmasötik olarak kabul edilebilir tuzlarının kullanımı.
IL148777A (en) Mirtazepine oral oral administration unit
AR027394A1 (es) Uso de mirtazapina para el tratamiento de trastornos del sueno
NO990949L (no) Anvendelse av PKC-inhibitorer til fremstilling av et medikament for behandling av AIDS
WO2004030623A3 (fr) Preparations de radioprotection a l'oxyde d'azote et leurs methodes d'utilisation
EP0940141A3 (fr) Utilisation d'inhibiteurs de la PKC pour la fabrication d'un médicament pour le traitement d'infections provoquées par le cytomégalovirus
MXPA05012696A (es) Formulaciones de agentes antiinflamatorios no esteroides para tratar angiogenesis ocular patologica.
EP0940143A3 (fr) Utilisation d'inhibiteurs de la PKC pour la fabrication d'un médicament pour le traitement de l'asthme
AU4937499A (en) Use of succinic acid or salts thereof and method of treating insulin resistance
MY136408A (en) Active substance combinations and therapies for treating abuse of alcohol
NO990948L (no) Anvendelse av PKC-inhibitorer til fremstilling av et medikament for behandling av HTLV-1-infeksjoner

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application